trial · primary record
pacritinib
Myelodysplastic Syndromes
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 160 |
| Primary completion | 2035-01-01 |
| Primary endpoint | Recommended phase 2 dose of pacritinib in participants 12-17 years of age |
| Registry ID | NCT06303193 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:36.711Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06303193
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.